Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Awakn Life Sciences Corp
(OP:
AWKNF
)
0.0800
UNCHANGED
Streaming Delayed Price
Updated: 11:38 AM EST, Nov 6, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Awakn Life Sciences Corp
< Previous
1
2
3
4
5
Next >
This Ketamine-Assisted Therapy Company Is Developing New Ways To Treat Alcohol Addiction
March 24, 2022
Picture credit: Martin Sanchez on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.
Via
Benzinga
Psychedelic And Cannabis Drug Stocks Continue Advance
February 13, 2022
This article updates the performances of 16 clinical-stage psychedelic and marijuana drug companies researching the treatment of a wide variety of mental illnesses.
Via
Talk Markets
Mindset Pharma, Cybin Among Top Psychedelic Movers Of Today
February 08, 2022
GAINERS: Awakn Life Sciences (OTC:AWKNF) shares closed up 3.51% at $1.62
Via
Benzinga
Mind Medicine, Allied Among Top Psychedelic Movers Of Today
February 02, 2022
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 5.04% at $0.17
Via
Benzinga
Awakn Life Sciences: Wake Up To The Huge Potential
November 01, 2021
The private global addiction treatment industry is currently valued at US$17.5 billion per year and forecast to increase to US$31.5 billion per year by 2027.
Via
Talk Markets
Has A Sugar Daddy Emerged In The Psychedelic Drug Industry?
January 31, 2022
One very large drug multinational has already been active in writing checks to finance drug development in the psychedelic drug industry.
Via
Talk Markets
The Psychedelic & Marijuana Drug Stocks Index Dropped -30% In January
January 30, 2022
This article updates the performances of 16 clinical-stage psychedelic and marijuana drug companies researching the treatment of a wide variety of mental illnesses.
Via
Talk Markets
Mind Medicine, Small Pharma Among Top Psychedelic Movers Of Today
January 27, 2022
GAINERS: Mindset Pharma (OTC:MSSTF) shares closed up 6.29% at $0.49
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 24, 2022
January 24, 2022
GAINERS: Field Trip Health (NASDAQ:
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 21, 2022
January 21, 2022
GAINERS: GH Research (NASDAQ:
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 20, 2022
January 20, 2022
GAINERS: Small Pharma (OTC:
Via
Benzinga
Revive Therapeutics, GH Research Among Top Psychedelic Movers Of Today
January 19, 2022
GAINERS: Revive Therapeutics (OTC:
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 18, 2022
January 18, 2022
GAINERS: Cybin (AMEX:
Via
Benzinga
Psyched: Delix Raises $30M, New Ketamine Study For Alcohol Use Disorder, FDA Approves Ketamine Trial For ALS
January 18, 2022
New Awakn Study Shows Ketamine Has Potential To Treat Alcoholism Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB:
Via
Benzinga
Ketamine Therapy Shows Potential In Treatment Of Alcohol Use Disorder, New Study Finds
January 11, 2022
Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB:AWKNF) publis...
Via
Benzinga
The Year In Review For Psychedelic Drug Stocks: 2021
December 21, 2021
2021 was two different
Via
Talk Markets
Marijuana & Psychedelic Compounds-Based Drug Stocks Now Down -16% YTD
December 17, 2021
A look at which index has done the best so far in December: the Marijuana Drug Stocks Index or the Psychedelic Compounds-Based Drug Stocks Index.
Via
Talk Markets
AWKNF: A Psychedelic's Stock Exhibiting Recent Price Appreciation
November 24, 2021
Awakn Health Sciences Corp's trading pattern over the past 10-day time span is an egregious example of a psychedelic stock that has exhibited recent price appreciation coupled with a surge in average...
Via
Talk Markets
Psychedelic Drug Stocks Continued To Decline Last Week
November 21, 2021
The 12 constituents in our Pure-Play Psychedelic Compounds-Based Drug Stocks Index declined -5.7% last week; it's now -16.1% so far in November.
Via
Talk Markets
New Options to Treat Alcohol Use Disorder
November 15, 2021
New Options to Treat Alcohol Use Disorder
Via
News Direct
Psychedelic Drug Stocks Have Plunged -10.6%, On Average, So Far In November
November 14, 2021
Our Pure-Play Psychedelic Compounds-Based Drug Stocks Index has declined -10.6% in the last 2 weeks; it's still up +7.8% since the end of September.
Via
Talk Markets
BioMedNewsBreaks – Mind Cure Health Inc.’s (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) iSTRYM Opening New Revenue Source, Helping Fuel Further Growth, Expansion
November 12, 2021
Via
Investor Brand Network
Compass Pathways Phase II Results: A Disappointment For Some, An Opportunity For Others
November 11, 2021
Compass Pathways reported
Via
Talk Markets
Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Growth Strategy Moves Forward with Awakn Life Sciences (NEO: AWKN) (OTCQB: AWKNF) Partnership for Ketamine-Assisted Psychotherapy Distribution
November 04, 2021
Via
Investor Brand Network
Psyched: MindMed's MDMA Program For Autism, Small Pharma's New Patent, NovaMentis' Orphan Drug Designation
November 01, 2021
The Week In Psychedelics:
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
PsychedelicNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Enters Strategic LOI to Distribute Ketamine Protocol
October 28, 2021
Via
Investor Brand Network
MINDCURE Signs LOI with Awakn Life Sciences to Distribute Ketamine Protocol for Alcohol Use Disorder into Clinics Across United States and Canada through iSTRYM, MINDCURE’s Digital Therapeutics Platform
October 28, 2021
Vancouver, BC – October 28, 2021 – Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology and research for psychedelics,...
Via
FinancialNewsMedia
Psyched: British PM Considers Psychedelics, New Partnership To Study Psilocybin For Autism, Compass Gets Another Patent
October 26, 2021
The Week In Psychedelics
Via
Benzinga
Psychedelic Stocks Rebounded 9% Last Week; Small Pharma Was Up 148%
October 24, 2021
The Psychedelic Compounds-Based Drug Stocks Index was up +8.9% last week albeit still down -18.5% YTD.
Via
Talk Markets
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
October 18, 2021
The Week In Psychedelics
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.